Cancer immunology explained

Cancer immunology (immuno-oncology) is an interdisciplinary branch of biology and a sub-discipline of immunology that is concerned with understanding the role of the immune system in the progression and development of cancer; the most well known application is cancer immunotherapy, which utilises the immune system as a treatment for cancer. Cancer immunosurveillance and immunoediting are based on protection against development of tumors in animal systems and (ii) identification of targets for immune recognition of human cancer.

Definition

Cancer immunology is an interdisciplinary branch of biology concerned with the role of the immune system in the progression and development of cancer; the most well known application is cancer immunotherapy, where the immune system is used to treat cancer.^{[1] [2]} Cancer immunosurveillance is a theory formulated in 1957 by Burnet and Thomas, who proposed that lymphocytes act as sentinels in recognizing and eliminating continuously arising, nascent transformed cells.^{[3] [4]} Cancer immunosurveillance appears to be an important host protection process that decreases cancer rates through inhibition of carcinogenesis and maintaining of regular cellular homeostasis.^[5] It has also been suggested that immunosurveillance primarily functions as a component of a more general process of cancer immunoediting.^[3]

Tumor antigens

See main article: Tumor antigen.

Tumors may express tumor antigens that are recognized by the immune system and may induce an immune response.^[6] These tumor antigens are either TSA (Tumor-specific antigen) or TAA (Tumor-associated antigen).^[7]

Tumor-specific

Tumor-specific antigens (TSA) are antigens that only occur in tumor cells. TSAs can be products of oncoviruses like E6 and E7 proteins of human papillomavirus, occurring in cervical carcinoma, or EBNA-1 protein of EBV, occurring in Burkitt's lymphoma cells.^{[8] [9]} Another example of TSAs are abnormal products of mutated oncogenes (e.g. Ras protein) and anti-oncogenes (e.g. p53).^[10]

Tumor-associated antigens

Tumor-associated antigens (TAA) are present in healthy cells, but for some reason they also occur in tumor cells. However, they differ in quantity, place or time period of expression.^[11] Oncofetal antigens are tumor-associated antigens expressed by embryonic cells and by tumors.^[12] Examples of oncofetal antigens are AFP (α-fetoprotein), produced by hepatocellular carcinoma, or CEA (carcinoembryonic antigen), occurring in ovarian and colon cancer.^{[13] [14]} More tumor-associated antigens are HER2/neu, EGFR or MAGE-1.^{[15] [16] [17]}

Immunoediting

Cancer immunoediting is a process in which immune system interacts with tumor cells. It consists of three phases: elimination, equilibrium and escape. These phases are often referred to as "the three Es" of cancer immunoediting. Both adaptive and innate immune system participate in immunoediting.^[18]

In the elimination phase, the immune response leads to destruction of tumor cells and therefore to tumor suppression. However, some tumor cells may gain more mutations, change their characteristics and evade the immune system. These cells might enter the equilibrium phase, in which the immune system does not recognise all tumor cells, but at the same time the tumor does not grow. This condition may lead to the phase of escape, in which the tumor gains dominance over immune system, starts growing and establishes immunosuppressive environment.^[19]

As a consequence of immunoediting, tumor cell clones less responsive to the immune system gain dominance in the tumor through time, as the recognized cells are eliminated. This process may be considered akin to Darwinian evolution, where cells containing pro-oncogenic or immunosuppressive mutations survive to pass on their mutations to daughter cells, which may themselves mutate and undergo further selective pressure. This results in the tumor consisting of cells with decreased immunogenicity and can hardly be eliminated. This phenomenon was proven to happen as a result of immunotherapies of cancer patients.^[20]

Tumor evasion mechanisms

• CD8+ cytotoxic T cells are a fundamental element of anti-tumor immunity. Their TCR receptors recognise antigens presented by MHC class I and when bound, the Tc cell triggers its cytotoxic activity. MHC I are present on the surface of all nucleated cells. However, some cancer cells lower their MHC I expression and avoid being detected by the cytotoxic T cells.^{[21] [22]} This can be done by mutation of MHC I gene or by lowering the sensitivity to IFN-γ (which influences the surface expression of MHC I).^[23] Tumor cells also have defects in antigen presentation pathway, what leads into down-regulation of tumor antigen presentations. Defects are for example in transporter associated with antigen processing (TAP) or tapasin.^[24] On the other hand, a complete loss of MHC I is a trigger for NK cells.^[25] Tumor cells therefore maintain a low expression of MHC I.
• Another way to escape cytotoxic T cells is to stop expressing molecules essential for co-stimulation of cytotoxic T cells, such as CD80 or CD86.^{[26] [27]}
• Tumor cells express molecules to induce apoptosis or to inhibit T lymphocytes:
  • Expression of FasL on its surface, tumor cells may induce apoptosis of T lymphocytes by FasL-Fas interaction.^[28]
  • Expression of PD-L1 on the surface of tumor cells leads to suppression of T lymphocytes by PD1-PD-L1 interaction.^[29]
• Tumor cells have gained resistance to effector mechanisms of NK and cytotoxic CD8+ T cell:
  • by loss of gene expression or inhibition of apoptotic signal pathway molecules: APAF1, Caspase 8, Bcl-2-associated X protein (bax) and Bcl-2 homologous antagonist killer (bak).^{[30] [31]}
  • by induction of expression or overexpression of antiapoptotic molecules: Bcl-2, IAP or XIAP.^{[32] [33]}

Tumor microenvironment

• Production of TGF-β by tumor cells and other cells (such as myeloid-derived suppressor cell) leads to conversion of CD4+ T cell into suppressive regulatory T cell (Treg)^[34] by a contact dependent or independent stimulation. In a healthy tissue, functioning Tregs are essential to maintain self-tolerance. In a tumor, however, Tregs form an immunosuppressive microenvironment.^[35]
• Tumor cells produce special cytokines (such as colony-stimulating factor) to produce myeloid-derived suppressor cell. These cells are heterogenous collection of cell types including precursors of dendritic cell, monocyte and neutrophil. MDSC have suppressive effects on T-lymphocytes, dendritic cells and macrophages. They produce immunosuppressive TGF-β and IL-10.^{[36] [25]}
• Another producer of suppressive TGF-β and IL-10 are tumor-associated macrophages, these macrophages have mostly phenotype of alternatively activated M2 macrophages. Their activation is promoted by TH type 2 cytokines (such as IL-4 and IL-13). Their main effects are immunosuppression, promotion of tumor growth and angiogenesis.^[37]
• Tumor cells have non-classical MHC class I on their surface, for example HLA-G. HLA-G is inducer of Treg, MDSC, polarise macrophages into alternatively activated M2 and has other immunosuppressive effects on immune cells.^[38]

Immunomodulation methods

Immune system is the key player in fighting cancer. As described above in mechanisms of tumor evasion, the tumor cells are modulating the immune response in their profit. It is possible to improve the immune response in order to boost the immunity against tumor cells.

• monoclonal anti-CTLA4 and anti-PD-1 antibodies are called immune checkpoint inhibitors:
  • CTLA-4 is a receptor upregulated on the membrane of activated T lymphocytes, CTLA-4 CD80/86 interaction leads to switch off of T lymphocytes. By blocking this interaction with monoclonal anti CTLA-4 antibody we can increase the immune response. An example of approved drug is ipilimumab.
  • PD-1 is also an upregulated receptor on the surface of T lymphocytes after activation. Interaction PD-1 with PD-L1 leads to switching off or apoptosis. PD-L1 are molecules which can be produced by tumor cells. The monoclonal anti-PD-1 antibody is blocking this interaction thus leading to improvement of immune response in CD8+ T lymphocytes. An example of approved cancer drug is nivolumab.^[39]
  • Chimeric Antigen Receptor T cell
    • This CAR receptors are genetically engineered receptors with extracellular tumor specific binding sites and intracellular signalling domain that enables the T lymphocyte activation.^[40]
  • Cancer vaccine
    • Vaccine can be composed of killed tumor cells, recombinant tumor antigens, or dendritic cells incubated with tumor antigens (dendritic cell-based cancer vaccine) ^[41]

Relationship to chemotherapy

See main article: cancer immunotherapy.

Obeid et al.^[42] investigated how inducing immunogenic cancer cell death ought to become a priority of cancer chemotherapy. He reasoned, the immune system would be able to play a factor via a 'bystander effect' in eradicating chemotherapy-resistant cancer cells.^{[43] [44] [45] [2]} However, extensive research is still needed on how the immune response is triggered against dying tumour cells.^{[2] [46]}

Professionals in the field have hypothesized that 'apoptotic cell death is poorly immunogenic whereas necrotic cell death is truly immunogenic'.^{[47] [48] [49]} This is perhaps because cancer cells being eradicated via a necrotic cell death pathway induce an immune response by triggering dendritic cells to mature, due to inflammatory response stimulation.^{[50] [51]} On the other hand, apoptosis is connected to slight alterations within the plasma membrane causing the dying cells to be attractive to phagocytic cells.^[52] However, numerous animal studies have shown the superiority of vaccination with apoptotic cells, compared to necrotic cells, in eliciting anti-tumor immune responses.^{[53] [54] [55] [56] [57]}

Thus Obeid et al.^[42] propose that the way in which cancer cells die during chemotherapy is vital. Anthracyclins produce a beneficial immunogenic environment. The researchers report that when killing cancer cells with this agent uptake and presentation by antigen presenting dendritic cells is encouraged, thus allowing a T-cell response which can shrink tumours. Therefore, activating tumour-killing T-cells is crucial for immunotherapy success.^[58]

However, advanced cancer patients with immunosuppression have left researchers in a dilemma as to how to activate their T-cells. The way the host dendritic cells react and uptake tumour antigens to present to CD4⁺ and CD8⁺ T-cells is the key to success of the treatment.^[59]

See also

• Oncogenomics

Notes and References

1. Miller JF, Sadelain M . The journey from discoveries in fundamental immunology to cancer immunotherapy . Cancer Cell . 27 . 4 . 439–49 . April 2015 . 25858803 . 10.1016/j.ccell.2015.03.007 . free .
2. Syn NL, Teng MW, Mok TS, Soo RA . De-novo and acquired resistance to immune checkpoint targeting . The Lancet. Oncology . 18 . 12 . e731–e741 . December 2017 . 29208439 . 10.1016/s1470-2045(17)30607-1 .
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD . Cancer immunoediting: from immunosurveillance to tumor escape . Nature Immunology . 3 . 11 . 991–8 . November 2002 . 12407406 . 10.1038/ni1102-991 . 3355084 .
4. Burnet M . Cancer; a biological approach. I. The processes of control . British Medical Journal . 1 . 5022 . 779–86 . April 1957 . 13404306 . 1973174 . 10.1136/bmj.1.3356.779 . 25382096 .
5. Kim R, Emi M, Tanabe K . Cancer immunoediting from immune surveillance to immune escape . Immunology . 121 . 1 . 1–14 . May 2007 . 17386080 . 2265921 . 10.1111/j.1365-2567.2007.02587.x .
6. Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagalà C, Astone A, Landolfi R, Barone C . The immune response to tumors as a tool toward immunotherapy . Clinical & Developmental Immunology . 2011 . 894704 . 2011 . 22190975 . 3235449 . 10.1155/2011/894704 . free .
7. Book: Storkus WJ, Finn OJ, DeLeo A, Zarour HM . 2003 . Categories of Tumor Antigens . https://www.ncbi.nlm.nih.gov/books/NBK12961/ . Kufe DW, Pollock RE, Weichselbaum RR, Bast Jr RC, Gansler TS, Holland JF, Frei III E . Holland-Frei Cancer Medicine . BC Decker . 6th .
8. Ramos CA, Narala N, Vyas GM, Leen AM, Gerdemann U, Sturgis EM, Anderson ML, Savoldo B, Heslop HE, Brenner MK, Rooney CM . Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies . Journal of Immunotherapy . 36 . 1 . 66–76 . January 2013 . 23211628 . 3521877 . 10.1097/CJI.0b013e318279652e .
9. Kelly GL, Stylianou J, Rasaiyaah J, Wei W, Thomas W, Croom-Carter D, Kohler C, Spang R, Woodman C, Kellam P, Rickinson AB, Bell AI . Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature . Journal of Virology . 87 . 5 . 2882–94 . March 2013 . 23269792 . 3571367 . 10.1128/JVI.03003-12 .
10. Disis ML, Cheever MA . Oncogenic proteins as tumor antigens . Current Opinion in Immunology . 8 . 5 . 637–42 . October 1996 . 8902388 . 10.1016/s0952-7915(96)80079-3.
11. Finn OJ . Human Tumor Antigens Yesterday, Today, and Tomorrow . Cancer Immunology Research . 5 . 5 . 347–354 . May 2017 . 28465452 . 5490447 . 10.1158/2326-6066.CIR-17-0112 .
12. Orell SR, Dowling KD . Oncofetal antigens as tumor markers in the cytologic diagnosis of effusions . Acta Cytologica . 27 . 6 . 625–9 . November 1983 . 6196931 .
13. Hsieh MY, Lu SN, Wang LY, Liu TY, Su WP, Lin ZY, Chuang WL, Chen SC, Chang WY . Alpha-fetoprotein in patients with hepatocellular carcinoma after transcatheter arterial embolization . Journal of Gastroenterology and Hepatology . 7 . 6 . 614–7 . November 1992 . 1283085 . 10.1111/j.1440-1746.1992.tb01495.x. 7112149 .
14. Khoo SK, MacKay EV . Carcinoembryonic antigen (CEA) in ovarian cancer: factors influencing its incidence and changes which occur in response to cytotoxic drugs . British Journal of Obstetrics and Gynaecology . 83 . 10 . 753–9 . October 1976 . 990213 . 10.1111/j.1471-0528.1976.tb00739.x. 6945964 .
15. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, Steinman RM . Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice . Breast Cancer Research . 14 . 2 . R39 . March 2012 . 22397502 . 3446373 . 10.1186/bcr3135 . free .
16. Li G, Wong AJ . EGF receptor variant III as a target antigen for tumor immunotherapy . Expert Review of Vaccines . 7 . 7 . 977–85 . September 2008 . 18767947 . 10.1586/14760584.7.7.977 . 207196758 .
17. Weon JL, Potts PR . The MAGE protein family and cancer . Current Opinion in Cell Biology . 37 . 1–8 . December 2015 . 26342994 . 4688208 . 10.1016/j.ceb.2015.08.002 .
18. Dunn GP, Old LJ, Schreiber RD . The three Es of cancer immunoediting . Annual Review of Immunology . 22 . 1 . 329–60 . 2004-03-19 . 15032581 . 10.1146/annurev.immunol.22.012703.104803 . 10.1.1.459.1918 .
19. Mittal D, Gubin MM, Schreiber RD, Smyth MJ . New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape . Current Opinion in Immunology . 27 . 16–25 . April 2014 . 24531241 . 4388310 . 10.1016/j.coi.2014.01.004 .
20. von Boehmer L, Mattle M, Bode P, Landshammer A, Schäfer C, Nuber N, Ritter G, Old L, Moch H, Schäfer N, Jäger E, Knuth A, van den Broek M . NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma . Cancer Immunity . 13 . 12 . 2013-07-15 . 23882157 . 3718732 .
21. Daniyan AF, Brentjens RJ . Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies . Nature Reviews. Clinical Oncology . 14 . 6 . 333–334 . June 2017 . 28397826 . 5536112 . 10.1038/nrclinonc.2017.49 .
22. Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S . Defective HLA class I antigen processing machinery in cancer . Cancer Immunology, Immunotherapy . 67 . 6 . 999–1009 . June 2018 . 29487978 . 10.1007/s00262-018-2131-2 . 8697037 . 3580894 .
23. Mojic M, Takeda K, Hayakawa Y . The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion . International Journal of Molecular Sciences . 19 . 1 . 89 . December 2017 . 29283429 . 5796039 . 10.3390/ijms19010089 . free .
24. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Nowsheen S, Yang X, Choi BK, Kwon BS . Immune evasion in cancer: Mechanistic basis and therapeutic strategies . Seminars in Cancer Biology . 35 Suppl . S185–S198 . December 2015 . 25818339 . 10.1016/j.semcancer.2015.03.004 . A broad-spectrum integrative design for cancer prevention and therapy . free .
25. Wagner M, Koyasu S . Cancer Immunoediting by Innate Lymphoid Cells . Trends in Immunology . 40 . 5 . 415–430 . May 2019 . 30992189 . 10.1016/j.it.2019.03.004 . 119093972 .
26. Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, Murillo O, Gonzalez A, Berasain C, Berraondo P, Fortes P, Prieto J, Colombo MP, Chen L, Melero I. February 2006. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Research. 66. 4. 2442–50. 10.1158/0008-5472.CAN-05-1681. 16489051. free. 10171/21800. free.
27. Pettit SJ, Ali S, O'Flaherty E, Griffiths TR, Neal DE, Kirby JA. April 1999. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro. Clinical and Experimental Immunology. 116. 1. 48–56. 10.1046/j.1365-2249.1999.00857.x. 1905215. 10209504.
28. Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P. April 2015. The role of CD95 and CD95 ligand in cancer. Cell Death and Differentiation. 22. 4. 549–59. 10.1038/cdd.2015.3. 4356349. 25656654.
29. Buchbinder EI, Desai A . CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition . American Journal of Clinical Oncology . 39 . 1 . 98–106 . February 2016 . 26558876 . 4892769 . 10.1097/COC.0000000000000239 .
30. Kim R, Kin T, Beck WT . Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy . Cancers . 16 . 5 . 984 . February 2024 . 38473345 . 10930821 . 10.3390/cancers16050984 . free .
31. Sordo-Bahamonde C, Lorenzo-Herrero S, Payer ÁR, Gonzalez S, López-Soto A . Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer . International Journal of Molecular Sciences . 21 . 10 . 3726 . May 2020 . 32466293 . 7279491 . 10.3390/ijms21103726 . free .
32. Frenzel A, Grespi F, Chmelewskij W, Villunger A . Bcl2 family proteins in carcinogenesis and the treatment of cancer . Apoptosis . 14 . 4 . 584–96 . April 2009 . 19156528 . 3272401 . 10.1007/s10495-008-0300-z .
33. Obexer P, Ausserlechner MJ . X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy . Frontiers in Oncology . 4 . 197 . 2014-07-28 . 25120954 . 4112792 . 10.3389/fonc.2014.00197 . free .
34. Polanczyk MJ, Walker E, Haley D, Guerrouahen BS, Akporiaye ET . + T cells . Journal of Translational Medicine . 17 . 1 . 219 . July 2019 . 31288845 . 6617864 . 10.1186/s12967-019-1967-3 . free .
35. Ha TY . The role of regulatory T cells in cancer . en . Immune Network . 9 . 6 . 209–35 . December 2009 . 20157609 . 2816955 . 10.4110/in.2009.9.6.209 .
36. Mantovani A . The growing diversity and spectrum of action of myeloid-derived suppressor cells . European Journal of Immunology . 40 . 12 . 3317–20 . December 2010 . 21110315 . 10.1002/eji.201041170 . free .
37. Quaranta V, Schmid MC . Macrophage-Mediated Subversion of Anti-Tumour Immunity . Cells . 8 . 7 . 747 . July 2019 . 31331034 . 10.3390/cells8070747 . free . 6678757 .
38. Lin A, Yan WH . Heterogeneity of HLA-G Expression in Cancers: Facing the Challenges . en . Frontiers in Immunology . 9 . 2164 . 2018 . 30319626 . 10.3389/fimmu.2018.02164 . free . 6170620 .
39. Brunner-Weinzierl MC, Rudd CE . CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy . Frontiers in Immunology . 9 . 2737 . 2018-11-27 . 30542345 . 6277866 . 10.3389/fimmu.2018.02737 . free .
40. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA . An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer . American Journal of Hematology . 94 . S1 . S3–S9 . May 2019 . 30680780 . 10.1002/ajh.25418 . free .
41. Book: Cellular and molecular immunology. Abbas AK . Elsevier . 2018 . 978-0-323-47978-3 . 409.
42. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G . Calreticulin exposure dictates the immunogenicity of cancer cell death . Nature Medicine . 13 . 1 . 54–61 . Jan 2007 . 17187072 . 10.1038/nm1523 . 12641252 .
43. Steinman RM, Mellman I . Immunotherapy: bewitched, bothered, and bewildered no more . Science . 305 . 5681 . 197–200 . Jul 2004 . 15247468 . 10.1126/science.1099688 . 2004Sci...305..197S . 5169245 .
44. Lake RA, van der Most RG . A better way for a cancer cell to die . The New England Journal of Medicine . 354 . 23 . 2503–4 . Jun 2006 . 16760453 . 10.1056/NEJMcibr061443 .
45. Zitvogel L, Tesniere A, Kroemer G . Cancer despite immunosurveillance: immunoselection and immunosubversion . Nature Reviews. Immunology . 6 . 10 . 715–27 . Oct 2006 . 16977338 . 10.1038/nri1936 . free .
46. Book: Zitvogel L, Casares N, Péquignot MO, Chaput N, Albert ML, Kroemer G . Immune Response Against Dying Tumor Cells . 84 . 131–79 . 2004 . 15246252 . 10.1016/S0065-2776(04)84004-5 . 978-0-12-022484-5 . Advances in Immunology .
47. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH . Cell death in health and disease: the biology and regulation of apoptosis . Seminars in Cancer Biology . 6 . 1 . 3–16 . Feb 1995 . 7548839 . 10.1006/scbi.1995.0002 .
48. Thompson CB . Apoptosis in the pathogenesis and treatment of disease . Science . 267 . 5203 . 1456–62 . Mar 1995 . 7878464 . 10.1126/science.7878464 . 1995Sci...267.1456T . 12991980 .
49. Igney FH, Krammer PH . Death and anti-death: tumour resistance to apoptosis . Nature Reviews. Cancer . 2 . 4 . 277–88 . Apr 2002 . 12001989 . 10.1038/nrc776 . 205470264 .
50. Steinman RM, Turley S, Mellman I, Inaba K . The induction of tolerance by dendritic cells that have captured apoptotic cells . The Journal of Experimental Medicine . 191 . 3 . 411–6 . Feb 2000 . 10662786 . 2195815 . 10.1084/jem.191.3.411 .
51. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM . Immune tolerance after delivery of dying cells to dendritic cells in situ . The Journal of Experimental Medicine . 196 . 8 . 1091–7 . Oct 2002 . 12391020 . 2194037 . 10.1084/jem.20021215 .
52. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux D, Vandenabeele P, Zhivotovsky B, Blagosklonny MV, Malorni W, Knight RA, Piacentini M, Nagata S, Melino G . Classification of cell death: recommendations of the Nomenclature Committee on Cell Death . Cell Death and Differentiation . 12 . 1463–7 . Nov 2005 . Suppl 2 . 16247491 . 10.1038/sj.cdd.4401724 . 2744427 .
53. Buckwalter MR, Srivastava PK . Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells . Cancer Immunity . 13 . 2 . 2013 . 23390373 . 3559190 .
54. Gamrekelashvili J, Ormandy LA, Heimesaat MM, Kirschning CJ, Manns MP, Korangy F, Greten TF . Primary sterile necrotic cells fail to cross-prime CD8(+) T cells . Oncoimmunology . 1 . 7 . 1017–1026 . Oct 2012 . 23170250 . 10.4161/onci.21098 . 3494616.
55. Janssen E, Tabeta K, Barnes MJ, Rutschmann S, McBride S, Bahjat KS, Schoenberger SP, Theofilopoulos AN, Beutler B, Hoebe K . Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway . Immunity . 24 . 6 . 787–99 . Jun 2006 . 16782034 . 10.1016/j.immuni.2006.03.024 . free .
56. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M . Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines . Journal of Immunology . 163 . 1 . 130–6 . Jul 1999 . 10.4049/jimmunol.163.1.130 . 10384108 . 27286647 . free .
57. Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, Manns MP, Greten TF . Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo . International Journal of Cancer . 103 . 2 . 205–11 . Jan 2003 . 12455034 . 10.1002/ijc.10777 . free .
58. Storkus WJ, Falo LD . A 'good death' for tumor immunology . Nature Medicine . 13 . 1 . 28–30 . Jan 2007 . 17206130 . 10.1038/nm0107-28 . 28596435 .
59. Dunn GP, Koebel CM, Schreiber RD . Interferons, immunity and cancer immunoediting . Nature Reviews. Immunology . 6 . 11 . 836–48 . Nov 2006 . 17063185 . 10.1038/nri1961 . 223082 .